Learnings From the Lampalizumab Chroma and Spectri Phase 3 Trials: Effect of Baseline Characteristics on Geographic Atrophy Progression

Related

• 

  Part 3: Implementing Clinical Trials in a Retina Practice: How to Get Started and Recruit Successfully (Part 3 of 3)

  Arshad M. Khanani, MD, MA, FASRS

  Carl J Danzig, MD

  Charles C Wykoff, MD, PhD, FASRS

  John D Pitcher, MD

  Nikolas JS London, MD, FACS, FASRS

  On Demand Cases, Courses, and Papers

  2018

• 

  Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial

  Jason Hsu, MD

  Annual Meeting Talks

  2021

• 

  Episode 1: Review of the Clarity Study with Dr. Amin Kherani

  Keyvan Koushan, MD, FRCSC

  Member Podcasts

  2017